Affordable Access

Access to the full text

Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab

Authors
  • Seban, Romain-David
  • Assié, Jean-Baptiste1, 2
  • Giroux-Leprieur, Etienne
  • Massiani, Marie-Ange
  • Soussan, Michael3
  • Bonardel, Gérald
  • Chouaid, Christos1
  • Playe, Margot3
  • Goldfarb, Lucas3
  • Duchemann, Boris
  • Mezquita, Laura
  • Girard, Nicolas
  • Champion, Laurence
  • 1 (C.C.)
  • 2 Inserm, Centre de Recherche des Cordeliers, Sorbonne University, Functionnal Genomics of Solid Tumors Laboratory, F-75006 Paris, France
  • 3 (L.G.)
Type
Published Article
Journal
Cancers
Publisher
MDPI AG
Publication Date
Aug 10, 2020
Volume
12
Issue
8
Identifiers
DOI: 10.3390/cancers12082234
PMID: 32785166
PMCID: PMC7463532
Source
PubMed Central
Keywords
Disciplines
  • Article
License
Green

Abstract

Background : We aimed to assess the clinical utility of a previously published score combining the total metabolic tumor volume (TMTV) on baseline FDG-PET/CT and pretreatment derived from the neutrophils to lymphocytes ratio (dNLR) for prognostication in NSCLC patients undergoing first-line immunotherapy (IT). Methods : In this multicenter retrospective study, 63 advanced NSCLC patients with a PD-L1 tumor proportion score (TPS) ≥50%, who underwent FDG-PET/CT before first-line IT, treated from January 2017 to September 2019, were enrolled. Associations between this score and the progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and overall response rate (ORR) were evaluated. Results : The median (m) PFS and mOS were 7.7 (95% CI 4.9–10.6) and 12.1 (8.6–15.6) months, respectively, and DCR and ORR were 65% and 58%, respectively. mOS was 17.9 months (14.6 not reached) for the good group versus 13.8 (95%CI 8.4–18.9) and 6.6 (CI 2.0–11.2) months for the intermediate and poor groups, respectively. mPFS was 15.1 (95%CI 12.1–20.0) months for the good group versus 5.2 (1.9–8.5) and 1.9 (95%CI 1.3–2.5) months for the intermediate and poor groups, respectively. The poor prognosis group was associated with DCR and ORR ( p < 0.05). Conclusions : The metabolic score combining TMTV on the baseline FDG-PET/CT scan and pretreatment dNLR was associated with the survival and response in a cohort of advanced NSCLC patients with ≥50% PD-L1 receiving frontline IT.

Report this publication

Statistics

Seen <100 times